We performed a limited evaluationof four free thyroxin (FT4) reagent kits: the Amerlex-M (AFT4), the Amerlite (LFT4), the MagicLite (MFT4), and the GammaCoat twostep RIA (GFT4). FT4 was measured in specimens from 201 subjects:19 healthy controls, 14 patients who were thyrotoxic, 13 who were hypothyroid, 59 who had a past history of thyroid disease, seven with thyroxin autoantibodies, seven who were taking amiodarone, and 82 who had no clinical indication of thyroid hormone abnormality. Of these 201 subjects, 78 had a low serum albumin (<35 g/L) and 27 had severe nonthyroidal illness. We also investigated 60 pregnant subjects. We found no correlation between thyroxin-binding globulin (TBG) and FT4 in any of the assays, and only the AFT4 method showed a significant correlation with albumin concentrations. abnormal concentrations or function of binding proteins (3, 4), and the presence of anti-thyroxin antibodies (5, 6).' New techniques involving different types of analogs have been introduced recently and claim to reduce some of these problems. We investigated two new chemiluminescent assays and compared them with the Amersham Amerlex-M free thyroxin assay and the Clinical Assays GammaCoat two-step (RIA) Fr4 assay, using specimens from a group of patients in various clinical states representative of those seen routinely at our hospital. We also used these assays to analyze specimens from a small group of normal controls and a group of pregnant women. We also studied the correlation of FF4 with various concentrations of albumin and thyroxin-binding globulin (TBG) and assessed the effects of thyroxin autoantibodies on results by these methods. Many of the subjects were sick, hospitalized patients. Seventy-eighthad a low serum albumin (<35 g/L) and 27 had severe, life-threatening illnesses. This represents the typical pattern of patients seen in our hospital.
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Materials and Methods

Subjects
We also investigated 60 clinically euthyroid pregnant women after a gestation period of at least 27 weeks. and an '251-labeled thyroxin analog for a solid-phase antibody. The GFT4 assay is based on the binding of the FT4 fraction to a solid-phase antibody. The unbound thyroxin fraction is then removed and the solid phase is washed, followed by incubation with an '251-labeled thyroxin tracer. Nonbound tracer is then removed and the radioactivity of the remaining tracer is counted.
The other two assays use chemiluminescence as the basis of detection. The LFl'4 is based on competition between FT4 and a horseradish peroxidase (EC 1.11.1.7)-labeled thyroxin analog for a solid-phase antibody. The MFT4, based on similar principles, involves the use of an acridinium ester-labeled thyroxin that competes for binding sites on antibodies immobilized to paramagnetic particles. The manufacturers claim that both these assays are not affected by variations in albumin concentration.
The reference range for the AFF4 assay, previously Effect of anti -thy roxin antibodies. One group of patients had results within the AFT4 reference range but above-normal results by other methods. Several patients were thyrotoxic and misclassified by the AFT4 value; several others were taking suggested for the LFT4 and MFT4 assays.
Effects of pregnancy.
The FT4 results for pregnant subjects in their third trimester are shown in Figure 3 .
All methods
show results in the lower part of the suggested reference range or below. The mean (and SD) was 9.1 (1.5) pmoIJL for AFT4, 9.1 (2.0) pmol/L for LFT4, 11 .0 (3.5) pmol/L for MFT4, and 11.6 (1.7) pmol/L for GFT4. The percentage of results falling below the suggested reference range for each method was 32% for AFT4, 57% for LFT4, 70% for MFT4, and 2% for GFT4. The majority of GFT4 results were in the lower half of the referencerange.
DiscussIon
We evaluated four FT4 kits in the setting of a hospital population; i.e., a significant proportion of patients were severely ill, as reflected in the high number of patients who had low albumin values. This group of patients frequently provides thyroid-function-test results that are difficult to interpret.
Albumin showed a significant correlation with the AF'F4 method, as has been previously reported (1, 2) . There was also a significant correlation between TBG 
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and AFT4 results. However, this was largely influenced by the strong correlation of TBG and albumin in these patients (r = 0.31, P <0.001 The AFT4 method was greatly influenced by patients with low albumin values, which skewed the distribution of euthyroid patients. The manufacturer's MFr4 reference range appeared too narrow, and the suggested upper range for the LFF4 assay does not correspond with the results in our patients. These findings indicate that the reference range for each kit should be determined in the user's laboratory.
FT4 results were low in pregnancy. This has been shown to be a physiological effect and not an artefact produced by the lower concentration of albumin in pregnancy (10, 11) . Our results show a similar decrease in Fr4 for all methods investigated.
The small number of values falling below the GFT4 range is due to its relatively wide suggested limits. Clinicians investigating or managing pregnant patients with thyroid disease need to be aware of this effect so that they can correctly interpret these patients' results.
Our findings show that the new nomsotopic analog assays are effectively free of interferencefrom variationsin concentrationsof TBG and albumin, but may stillbe affected by the presence of autoantibodies to thyroxin. All gave lower mean values in pregnant patients.
The manufacturers' suggested referenceranges also need to be re-assessedfor each laboratory that uses these methods. The GFT4 assay providesresultsthatare the least subject to interferencesand that also best correlatewith the patients' clinical state.
Addendum.
Since thisstudy was performed, the reference range suggested for the MFT4 assay has been amended to 10.7to 23.6 pmol/L. We also believe that the reagents for this kit have been revised.
